Izumep Capsule SR is a combination pharmaceutical formulation containing Domperidone 30mg and Esomeprazole 40mg, designed for the management of gastrointestinal disorders characterized by acid reflux, dyspepsia, and delayed gastric emptying. Domperidone, a peripheral dopamine D2 receptor antagonist, facilitates gastric motility and accelerates gastric emptying, thereby alleviating symptoms such as nausea, vomiting, and bloating. Esomeprazole, a proton pump inhibitor, suppresses gastric acid secretion by irreversibly inhibiting the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells, providing effective relief from acid-related conditions including gastroesophageal reflux disease (GERD), erosive esophagitis, and peptic ulcers. The sustained-release formulation ensures prolonged therapeutic plasma concentrations, enhancing patient compliance and symptom control. Izumep Capsule SR is indicated in patients requiring both acid suppression and prokinetic therapy to improve upper gastrointestinal motility and reduce acid exposure. It should be administered as prescribed by a healthcare professional, with caution advised in patients with known hypersensitivity to its components, significant hepatic impairment, or underlying cardiac conditions due to the potential risk of QT interval prolongation associated with Domperidone. Regular monitoring and adherence to recommended dosages are essential to maximize efficacy and minimize adverse effects.